About
Modalis develops epigenome editing technology, CRISPR-GNDM®, to selectively control gene expression in target cells aiming to treat diseases by regulating the epigenome without altering DNA sequences.
Explore Modalis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.